Novel diabetes drug candidate shows promising properties in human islets and mouse models

Researchers have discovered a new drug candidate that offers a major advance in the treatment for diabetes. Tested on isolated human and mouse pancreatic islets, mouse and rat cell cultures and animal models of both Type 1 and Type 2 diabetes, the experimental drug significantly improved four detrimental characteristics of diabetes: hyperglycemia; hyperglucagonemia, elevation in the hormone glucagon; excessive production of glucose by the liver; and fatty liver, known as hepatic steatosis.